Arachidonic acid‐containing phosphatidylcholine characterized by consolidated plasma and liver lipidomics as an early onset marker for tamoxifen‐induced hepatic phospholipidosis
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Applied Toxicology"
DOI: 10.1002/jat.3442
Abstract: Lipid profiling has emerged as an effective approach to not only screen disease and drug toxicity biomarkers but also understand their underlying mechanisms of action. Tamoxifen, a widely used antiestrogenic agent for adjuvant therapy against… read more here.
Keywords: plasma liver; tamoxifen induced; liver; arachidonic acid ... See more keywords
A systemic combined nontargeted and targeted LC-MS based metabolomic strategy of plasma and liver on pathology exploration of alpha-naphthylisothiocyanate induced cholestatic liver injury in mice.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of pharmaceutical and biomedical analysis"
DOI: 10.1016/j.jpba.2019.04.009
Abstract: The pathology of cholestatic liver injury (CLI) was complicated, which has limited the development of anti-cholestatic drugs for a long period. Metabolomic researches focused on global and dynamic changes of the organism could shed some… read more here.
Keywords: plasma liver; liver; pathology; liver injury ... See more keywords
Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-04931-y
Abstract: Current standard-of-care treatment of chronically infected hepatitis C virus (HCV) patients involves direct-acting antivirals (DAA). However, concerns exist regarding the emergence of drug -resistant variants and subsequent treatment failure. In this study, we investigate potential… read more here.
Keywords: plasma liver; treatment; treatment patients; direct acting ... See more keywords
Identification of Liver and Plasma microRNAs in Chronic Hepatitis B Virus infection
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Cellular and Infection Microbiology"
DOI: 10.3389/fcimb.2022.790964
Abstract: Background and Aims With current standard of care a functional cure for Chronic Hepatitis B (CHB) is only achieved in 1-3% of patients and therefore novel therapies are needed. Disease activity during CHB can be… read more here.
Keywords: plasma liver; liver; chronic hepatitis; plasma ... See more keywords